The initial coverage focuses on an in-depth quarterly analysis of the evolving multiple myeloma market
EXTON, Pa., February 13, 2018 /PRNewswire/ – Spherix Global Insights is a recognized market intelligence agency providing independent coverage of the autoimmune, multiple sclerosis, and nephrology markets. Unlike other firms offering syndicated reports, Spherix derives actionable insights from its frequent, commercially-focused primary market research which is highly customized to each client’s unique needs. Possessing unrivalled content expertise and collaborating with a network of highly engaged specialists are essential elements distinguishing Spherix in the business analytics and intelligence space.
Oncology is a large, complex, and fast-moving market. In the past year, multiple clients have encouraged Spherix to offer their high value market intelligence for the oncology sector. After careful consideration, Spherix has entered into a partnership with several oncology experts to introduce a new quarterly series, RealTime Dynamix: Multiple Myeloma in 2018.
Ike Nicoll and Carlton Sedberry have well-established, stellar reputations as consultants and operators in the oncology space. Collectively, they bring extensive expertise in commercial assessments, market access strategy, and knowledge of the clinical aspects in oncology. According to Sedberry, “Biopharma companies and external stakeholders are increasingly seeking independent and comprehensive perspectives of the commercially relevant questions facing their products in rapidly evolving disease states.” Having spent years working with oncologists, Nicoll added that “We see a unique opportunity to pair our passion, knowledge, and expertise with Spherix’s market intelligence model to provide clients with an unparalleled, real time view of the rapidly changing oncology market, and what it means to their current and emerging products.”
Over the past several months, the oncology workgroup has focused on three foundational elements needed to launch an oncology solution, including (1) building a representative network of hematologists/oncologists with whom to collaborate, (2) determining which areas of oncology merit this in-depth, frequent coverage, and (3) working with multiple stakeholders including key opinion leaders, biopharma commercial teams, financial analysts, and select payers to assure that our content is comprehensive and cutting edge.
“What we do here at Spherix is pretty unique. The passion and commercially savvy perspectives that Ike and Carlton bring to this space align superbly with our model,” says Jennifer Robinson, President of Spherix. “After several months of development, we are thrilled to be launching our initial wave of independent, primary research covering the multiple myeloma market.”
RealTime Dynamix: Multiple Myeloma will explore the evolving treatment paradigm in the US market, identify current and potential barriers to adoption/utilization of novel agents with current and expanding indications, and explore physicians’ perspectives on current issues and controversies in this disease such as timing, combinations, sequencing of novel agents, the goal of therapy and the concept of cure. Further, the study will explore anticipated future changes, evaluate the unmet needs within the market, and assess the commercial potential for late-stage pipeline agents. The first report will be available in March with a core emphasis on trends related to Amgen’s Kyprolis and Xgeva, BMS’ Empliciti, Celgene’s Pomalyst and Revlimid, Janssen’s Darzalex, Novartis’ Farydak, and Takeda’s Ninlaro and Velcade.
About Spherix Global Insights
Spherix Global Insights is an independent business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.
All company, brand or product names in this document are trademarks of their respective holders.
To view media coverage of this release, click here.